Creative Planning Has $210,000 Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Creative Planning lessened its stake in Twist Bioscience Co. (NASDAQ:TWST) by 8.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,646 shares of the company’s stock after selling 405 shares during the quarter. Creative Planning’s holdings in Twist Bioscience were worth $210,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. boosted its position in shares of Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after purchasing an additional 613,057 shares in the last quarter. Fred Alger Management LLC lifted its holdings in Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares in the last quarter. Victory Capital Management Inc. grew its stake in Twist Bioscience by 4,133.1% in the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after acquiring an additional 300,891 shares during the period. Farallon Capital Management LLC acquired a new position in Twist Bioscience in the second quarter valued at about $9,462,000. Finally, Driehaus Capital Management LLC raised its position in shares of Twist Bioscience by 63.0% during the second quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock worth $19,152,000 after purchasing an additional 150,260 shares during the period.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Barclays reduced their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. upped their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

Insider Transactions at Twist Bioscience

In related news, COO Patrick John Finn sold 6,239 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $278,259.40. Following the completion of the transaction, the chief operating officer now owns 231,401 shares of the company’s stock, valued at $10,320,484.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CFO Adam Laponis sold 856 shares of the company’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the transaction, the chief financial officer now directly owns 73,397 shares in the company, valued at approximately $3,068,728.57. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Patrick John Finn sold 6,239 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $278,259.40. Following the completion of the transaction, the chief operating officer now directly owns 231,401 shares of the company’s stock, valued at approximately $10,320,484.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,356 shares of company stock valued at $3,205,239. 3.92% of the stock is owned by corporate insiders.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $45.40 on Monday. The firm has a market cap of $2.66 billion, a PE ratio of -11.88 and a beta of 1.78. The stock’s fifty day moving average price is $43.69 and its two-hundred day moving average price is $45.74. Twist Bioscience Co. has a one year low of $15.85 and a one year high of $60.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.